Patents Assigned to Bioinvent International AB
-
Publication number: 20230322933Abstract: The present invention generally relates to combinations for use in therapeutic systems and antibody dosage regimens, and uses thereof. Also described herein is a model for predicting if a therapeutic antibody binding to a human target will be associated with a tolerability issue in connection with intravenous administration and/or for predicting if pre-treatment, altered administration route or modification of the antibody can prevent a tolerability issue associated with intravenous administration to a human of the therapeutic antibody. The model comprises administering the antibody intravenously or intraperitoneally to mice and observing the mice immediately after the administration for any transient display of the macroscopic symptoms isolation and decreased activity.Type: ApplicationFiled: June 4, 2021Publication date: October 12, 2023Applicant: BIOINVENT INTERNATIONAL ABInventors: Björn FRENDÉUS, Linda MARTENSSON, Ingrid TEIGE, Ingrid KARLSSON
-
Patent number: 10351970Abstract: The present invention relates to screening methods and, in particular, to methods of screening anti-ligand libraries for identifying anti-ligands specific for differentially and/or infrequently expressed ligands. The method comprises the steps of providing a library of anti-ligands: providing a first subtractor ligand; providing a second target ligand; determining the amount of the first and second target ligands using one or more equations derived from the universal law of mass action; providing the determined amount of a first subtractor ligand; providing the determined amount of a second target ligand; providing separation means capable of use to isolate anti-ligand bound to the second target ligand from anti-ligand bound to the first subtractor ligand; exposing the library of to the first and second target ligands to permit binding of anti-ligands to ligands; and using the separation means to isolate the anti-ligand bound to second target ligand.Type: GrantFiled: February 29, 2016Date of Patent: July 16, 2019Assignee: BioInvent International ABInventor: Björn Frendéus
-
Patent number: 10191049Abstract: The present invention relates to improved screening methods and, in particular, to methods of screening anti-ligand libraries for identifying anti-ligands specific for differentially and/or infrequently expressed ligands.Type: GrantFiled: September 20, 2012Date of Patent: January 29, 2019Assignee: BioInvent International ABInventors: Bjorn Frendeus, Jenny Mattsson
-
Publication number: 20180221482Abstract: There is provided antibodies or antigen-binding fragments thereof with binding specificity for ICAM-1, together with further anti-cancer agents, and compositions thereof, for use in the treatment of cancer.Type: ApplicationFiled: December 19, 2017Publication date: August 9, 2018Applicant: BioInvent International ABInventors: Björn Frendéus, Markus Hansson
-
Patent number: 9803013Abstract: The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce cell death of the target cell. There is also provided methods of and pharmaceutical compositions for cell death induction and uses thereof.Type: GrantFiled: April 11, 2014Date of Patent: October 31, 2017Assignee: BioInvent International ABInventors: Björn Frendéus, Roland Carlsson, Ingrid Teige, Linda Mårtensson
-
Publication number: 20170107293Abstract: Description of a composition comprising an antibody molecule and an agent for use in the treatment of refractory cancer and/or relapsed cancer, and of a method of treating refractory cancer and/or relapsed cancer comprising administering an antibody molecule and an agent. There are also described kits comprising the antibody molecule and agents.Type: ApplicationFiled: May 15, 2015Publication date: April 20, 2017Applicant: BIOINVENT INTERNATIONAL ABInventors: Björn Frendéus, Ingrid Teige, Linda Mårtensson, Mark Cragg, Ali Roghanian
-
Publication number: 20160312383Abstract: The present invention relates to screening methods and, in particular, to methods of screening anti-ligand libraries for identifying anti-ligands specific for differentially and/or infrequently expressed ligands. The method comprises the steps of providing a library of anti-ligands; providing a first subtractor ligand; providing a second target ligand; determining the amount of the first and second target ligands using one or more equations derived from the universal law of mass action; providing the determined amount of a first subtractor ligand; providing the determined amount of a second target ligand: providing separation means capable of use to isolate anti-ligand bound to the second target ligand from anti-ligand bound to the first subtractor ligand; exposing the library of to the first and second target ligands to permit binding of anti-ligands to ligands; and using the separation means to isolate the anti-ligand bound to second target ligand.Type: ApplicationFiled: February 29, 2016Publication date: October 27, 2016Applicant: BioInvent International ABInventor: Björn Frendéus
-
Publication number: 20160280788Abstract: There is provided antibodies or antigen-binding fragments thereof with binding specificity for ICAM-1, for use in the treatment of cancer in patients who have previously been treated for cancer and either not responded to said treatment or have previously responded to said treatment and subsequently relapsed.Type: ApplicationFiled: January 27, 2016Publication date: September 29, 2016Applicant: BioInvent International ABInventors: Markus Hansson, Björn Frendéus
-
Publication number: 20140314793Abstract: The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce cell death of the target cell. There is also provided methods of and pharmaceutical compositions for cell death induction and uses thereof.Type: ApplicationFiled: April 11, 2014Publication date: October 23, 2014Applicant: BIOINVENT INTERNATIONAL ABInventors: Björn Frendéus, Roland Carlsson, Ingrid Teige, Linda Mårtensson
-
Publication number: 20140242072Abstract: The invention relates to the use of an antibody or an antigen-binding fragment thereof with binding specificity for ICAM-1, or a variant, fusion or derivative of said antibody or an antigen-binding fragment with binding specificity for ICAM-1, for the treatment of a multiple-myeloma-related disorder. The invention also relates to methods for the administration of such antibodies, fragments, variants, fusion and derivatives thereof.Type: ApplicationFiled: September 27, 2012Publication date: August 28, 2014Applicant: BIOINVENT INTERNATIONAL ABInventor: Markus Hansson
-
Publication number: 20140227249Abstract: The present invention relates to improved screening methods and, in particular, to methods of screening anti-ligand libraries for identifying anti-ligands specific for differentially and/or infrequently expressed ligands.Type: ApplicationFiled: September 20, 2012Publication date: August 14, 2014Applicant: BIOINVENT INTERNATIONAL ABInventors: Bjorn Frendeus, Jenny Mattsson
-
Publication number: 20140200152Abstract: The present invention relates to screening methods and, in particular, to methods of screening anti-ligand libraries for identifying anti-ligands specific for differentially and/or infrequently expressed ligands. The method comprises the steps of providing a library of anti-ligands; providing a first subtractor ligand; providing a second target ligand; determining the amount of the first and second target ligands using one or more equations derived from the universal law of mass action; providing the determined amount of a first subtractor ligand; providing the determined amount of a second target ligand; providing separation means capable of use to isolate anti-ligand bound to the second target ligand from anti-ligand bound to the first subtractor ligand; exposing the library of to the first and second target ligands to permit binding of anti-ligands to ligands; and using the separation means to isolate the anti-ligand bound to second target ligand.Type: ApplicationFiled: October 15, 2013Publication date: July 17, 2014Applicant: BIOINVENT INTERNATIONAL ABInventor: Björn Frendéus
-
Patent number: 8758749Abstract: The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce apoptosis of the target cell. There is also provided methods of and pharmaceutical compositions for apoptosis induction and uses thereof.Type: GrantFiled: March 22, 2011Date of Patent: June 24, 2014Assignee: BioInvent International ABInventors: Bjorn Frendéus, Anne-Christine Carlsson
-
Publication number: 20120077710Abstract: The present invention relates to a method for in vivo molecular evolution of antibody function. According to the present invention, a nucleic acid encoding a CDR that is normally contained in a framework (the “original framework”), which differs from a selected master framework, is amplified from an immunoglobulin gene and is inserted into a nucleic acid encoding the selected master framework. The invention further provides an antibody library, such as a phage display library, and methods of making the same.Type: ApplicationFiled: May 16, 2011Publication date: March 29, 2012Applicant: BIOINVENT INTERNATIONAL ABInventors: Mats Ohlin, Eskil Soderlind, Roland Carlsson
-
Patent number: 7943744Abstract: The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce apoptosis of the target cell. There is also provided methods of and pharmaceutical compositions for apoptosis induction and uses thereof.Type: GrantFiled: December 8, 2006Date of Patent: May 17, 2011Assignee: BioInvent International ABInventors: Björn Frendéus, Roland Carlsson, Anne-Christine Carlsson, legal representative
-
Publication number: 20100119526Abstract: DLL4-binding antibodies, specifically antibodies preventing Notch signaling and internalization of DLL4, can: more efficiently than inhibitors only preventing DLL4-mediated Notch-signaling disrupt angiogenesis and pathological processes including tumor growth.Type: ApplicationFiled: January 28, 2008Publication date: May 13, 2010Applicant: BIOINVENT INTERNATIONAL ABInventor: Mats Hellström
-
Publication number: 20090208503Abstract: The use of immunotherapy against oxidised LDL to induce regression of pre-existing atherosclerotic lesions in an individual. The immunotherapy can be passive immunotherapy utilising antibodies that bind to epitopes present on oxidised LDL, or active immunotherapy utilising a vaccine composition for induction of an immune response against epitopes present on oxidised LDL.Type: ApplicationFiled: September 4, 2006Publication date: August 20, 2009Applicant: BIOINVENT INTERNATIONAL ABInventors: Roland Carlsson, Anne-Christine Carlsson, Jan Nilsson
-
Patent number: 7521046Abstract: The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method for preparing such antibodies, and a method for treating a mammal, preferably a human using such an antibody to provide for passive immunization.Type: GrantFiled: October 30, 2007Date of Patent: April 21, 2009Assignee: BIOINVENT International ABInventors: Jan Nilsson, Roland Carlsson, Jenny Bengtsson, Leif Strandberg
-
Publication number: 20090060915Abstract: The present invention relates to prophylactic or therapeutic treatments for hindering blood vessel formation (for example, angiogenesis) for example for hindering tumour growth. In particular, the invention relates to a vaccine or medicament comprising a whole angiomotin molecule or a fragment thereof which may be used to generate immune responses to angiomotin. The invention also provides antibodies specific for a whole angiomotin molecule or a fragment thereof for use in prophylactic or therapeutic treatments.Type: ApplicationFiled: April 28, 2006Publication date: March 5, 2009Applicant: BIOINVENT INTERNATIONAL ABInventor: Lars Holmgren
-
Patent number: 7432083Abstract: The present invention relates to a method for in vitro creation of molecular libraries evolution of protein function. Particularly, it relates to variability and modification of protein function by shuffling polynucleotide sequence segments. A protein of desired characteristics can be obtained by incorporating variant peptide regions (variant motifs) into defined peptide regions (scaffold sequence). The variant motifs can be obtained from parent DNA which has been subjected to mutagenesis to create a plurality of differently mutated derivatives thereof or they can be obtained from in vivo sequences. These variant motifs can then be incorporated into a scaffold sequence and the resulting coded protein screened for desired characteristics. This method is ideally used for obtaining antibodies with desired characteristics by isolating individual CDR DNA sequences and incorporating them into a scaffold which may, for example, be from a totally different antibody.Type: GrantFiled: April 19, 2005Date of Patent: October 7, 2008Assignee: Bioinvent International ABInventors: Ulf Hans Eskil Soderlind, Carl Arne Krister Borrebaeck